Stock Traders Purchase Large Volume of Avalo Therapeutics Put Options (NASDAQ:AVTX)

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of unusually large options trading activity on Monday. Stock traders purchased 6,807 put options on the stock. This is an increase of 228% compared to the typical daily volume of 2,076 put options.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AVTX shares. HC Wainwright reduced their price objective on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Citigroup restated an “outperform” rating on shares of Avalo Therapeutics in a report on Wednesday, May 6th. BTIG Research lifted their price target on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Mizuho increased their price objective on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Finally, Wedbush cut their target price on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Avalo Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $48.13.

Avalo Therapeutics Trading Up 0.8%

NASDAQ:AVTX traded up $0.10 during trading hours on Monday, hitting $13.20. The stock had a trading volume of 411,877 shares, compared to its average volume of 1,084,684. Avalo Therapeutics has a 1-year low of $4.20 and a 1-year high of $24.27. The business has a 50 day simple moving average of $15.80 and a two-hundred day simple moving average of $16.36. The company has a market cap of $693.92 million, a PE ratio of -2.41 and a beta of 0.83.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. Research analysts expect that Avalo Therapeutics will post -2.72 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mittie Doyle sold 3,970 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70. Following the completion of the transaction, the insider owned 3,622 shares of the company’s stock, valued at approximately $65,232.22. This represents a 52.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,457 shares of Avalo Therapeutics stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $13.23, for a total transaction of $111,886.11. Following the completion of the transaction, the chief financial officer owned 423 shares in the company, valued at approximately $5,596.29. This trade represents a 95.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 138,078 shares of company stock valued at $2,501,346. Insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. BIT Capital GmbH purchased a new position in Avalo Therapeutics in the third quarter valued at about $25,000. PFS Partners LLC raised its position in shares of Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Avalo Therapeutics in the 2nd quarter valued at approximately $56,000. Dimensional Fund Advisors LP purchased a new position in shares of Avalo Therapeutics during the 3rd quarter valued at approximately $143,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Avalo Therapeutics during the first quarter worth approximately $174,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.